Non-exclusive discount agreements for medicines containing golimumab under an open-house model

Summary

The procurement concerns non-exclusive pharmaceutical discount agreements for medicines containing the active substance golimumab (ATC code L04AB06), concluded through an open-house model. The agreements are available to interested pharmaceutical companies on the stated terms; there is no exclusive supply arrangement, and no minimum purchase volume is guaranteed. The agreements end no later than 30 June 2028, although the procedure may be ended earlier.